Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 5,479 Shares of Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of Bioventus stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $9.79, for a total value of $53,639.41. Following the sale, the chief financial officer now directly owns 131,963 shares in the company, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62.

Bioventus Price Performance

Shares of BVS stock traded down $0.29 on Tuesday, reaching $9.43. The company’s stock had a trading volume of 231,433 shares, compared to its average volume of 423,781. The stock’s fifty day simple moving average is $10.11 and its 200-day simple moving average is $11.01. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The company has a market capitalization of $765.29 million, a price-to-earnings ratio of -15.46 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BVS shares. Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Institutional Trading of Bioventus

A number of large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its holdings in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after acquiring an additional 1,786 shares during the last quarter. Plato Investment Management Ltd bought a new position in shares of Bioventus during the 4th quarter valued at approximately $38,000. Virtus Fund Advisers LLC bought a new position in shares of Bioventus during the 3rd quarter valued at approximately $42,000. Quest Partners LLC bought a new stake in Bioventus in the third quarter worth $51,000. Finally, Quarry LP purchased a new position in Bioventus during the third quarter worth $59,000. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.